Financial results for the period ended September 30, 2026
As filed · Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsMajormateriality 75 out of 100
What happened
FactFinancial results for the period ended September 30, 2026. The Unaudited Financial Results (Standalone and Consolidated) for the quarter and half. Limited Review Report on the Unaudited Financial Results (Standalone and Consolidated).
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Guidance
WithdrawnEarlierFY27
Revenue: ~ 3x of FY24
NowFY27
Expect technology transfer revenues to start in Q4’FY27
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe stated timeline moved by -12 quarter(s) (FY30 to Q4 FY27).confidence 60%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- EBITDA Margin: More than 25% (management committed by FY30)
- Revenue: ~ 3x of FY24 (management committed by FY30)
Evidence
- Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY27
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%